HUMA News and Press, Humacyte Inc. From 10/07/25

A look at the top 10 most actives in the United States Nuburu Inc. (BURU) rose 36.0% to $0.3468 on volume of 191,450,318 shares Zeta Network Group (ZNB) rose 125.3% to $3.74 on volume of 105,438,624 shares Trilogy Metals Inc. (TMQ) rose 214.9% to $6.5815 on volume of 86,667,992 shares Env...

2025-10-07 09:23:51 ET More on Humacyte Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript Humacyte rises after positive data from humanitarian study of Symvess Humacyte, Senseonics jump as ...

DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it entered into a securities purchase agreement with certain f...

2025-10-06 16:09:46 ET More on Humacyte Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript Humacyte, Senseonics jump as Barclays issues new Overweight ratings Humacyte targets over 200 hospi...

- Results published in Oxford Academic’s Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency - DURHAM, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq:...

– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esophagus ...

2025-09-18 11:16:31 ET Humacyte, Inc. (NASDAQ: HUMA ) announced the publication of preclinical results showing that its Coronary Tissue Engineered Vessel (CTEV) -- also known as a small-diameter ATEV (sdATEV) -- could offer a promising alternative for coronary artery bypass grafting...

- Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted CTEVs remained patent through six months, demonstrated adaptive remodeling, and r...

- Results were published in the Journal of Vascular Surgery - - Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surgical procedures - - Patients treated with Symvess were observed to have high leve...

2025-09-12 17:09:49 ET More on Humacyte Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway Read the full article on Seeking Alpha ...